‌

US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors

Patent 11873304 was granted and assigned to Incyte on January, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Heeoon Han0

Zhiyong Yu0

Wenqing Yao0

Liangxing Wu0

Le Zhao0

Xiaozhao Wang0

Matthew S. McCammant0

Date of Patent

January 16, 2024

0

Patent Application Number

171593450

Date Filed

January 27, 2021

0

Patent Citations

US Patent 7488802 Antibodies against PD-1

0

US Patent 7501411 Triazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases

0

US Patent 7511050 Purinone derivatives as HM74A agonists

0

US Patent 7563788 Substituted Imidazo[1,2-a]pyridines as Antibacterial Agents

0

US Patent 7635757 B7-4 Antibodies and uses therefor

0

US Patent 7674791 Triazolopyrazines and methods of making and using the same

0

US Patent 7700594 Fused bicyclic mTOR inhibitors

0

US Patent 6921762 Substituted indolizine-like compounds and methods of use

0

...

Patent Primary Examiner

0

CPC Code

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11873304 Fused pyrimidine derivatives as A2A/A2B inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool